What is William Blair’s Forecast for ELAN FY2025 Earnings?

Elanco Animal Health Incorporated (NYSE:ELAN) – Stock analysts at William Blair upped their FY2025 earnings per share estimates for Elanco Animal Health in a research note issued on Wednesday, May 7th. William Blair analyst B. Vazquez now expects that the company will post earnings of $0.83 per share for the year, up from their prior estimate of $0.80. The consensus estimate for Elanco Animal Health’s current full-year earnings is $0.91 per share. William Blair also issued estimates for Elanco Animal Health’s Q1 2026 earnings at $0.31 EPS.

ELAN has been the topic of a number of other reports. UBS Group dropped their target price on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Piper Sandler lowered their price objective on Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a report on Thursday, March 6th. Stifel Nicolaus boosted their price objective on Elanco Animal Health from $13.00 to $15.00 and gave the company a “buy” rating in a report on Thursday, May 8th. Barclays lowered their price objective on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Finally, Morgan Stanley lowered their price objective on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $15.00.

Elanco Animal Health Stock Up 7.2%

Shares of NYSE ELAN opened at $12.82 on Monday. Elanco Animal Health has a 1 year low of $8.02 and a 1 year high of $18.80. The firm has a market cap of $6.36 billion, a price-to-earnings ratio of 32.04, a PEG ratio of 2.50 and a beta of 1.49. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The stock’s 50-day simple moving average is $9.93 and its 200-day simple moving average is $11.42.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.31 by $0.06. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business had revenue of $1.19 billion for the quarter, compared to analyst estimates of $1.17 billion. During the same period in the previous year, the company earned $0.34 earnings per share. The company’s revenue for the quarter was down 1.0% compared to the same quarter last year.

Insider Buying and Selling at Elanco Animal Health

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction on Tuesday, March 11th. The stock was bought at an average cost of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the purchase, the director now directly owns 111,459 shares in the company, valued at approximately $1,136,881.80. The trade was a 9.86% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.89% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Elanco Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of ELAN. Wilmington Savings Fund Society FSB acquired a new position in shares of Elanco Animal Health during the third quarter worth approximately $35,000. Franklin Resources Inc. boosted its position in shares of Elanco Animal Health by 14.0% during the third quarter. Franklin Resources Inc. now owns 372,230 shares of the company’s stock worth $5,349,000 after buying an additional 45,795 shares during the period. 180 Wealth Advisors LLC boosted its position in shares of Elanco Animal Health by 10.4% during the fourth quarter. 180 Wealth Advisors LLC now owns 26,732 shares of the company’s stock worth $324,000 after buying an additional 2,525 shares during the period. Mitchell & Pahl Private Wealth LLC boosted its position in shares of Elanco Animal Health by 12.6% during the fourth quarter. Mitchell & Pahl Private Wealth LLC now owns 43,728 shares of the company’s stock worth $530,000 after buying an additional 4,881 shares during the period. Finally, Hedges Asset Management LLC boosted its position in shares of Elanco Animal Health by 15.7% during the fourth quarter. Hedges Asset Management LLC now owns 110,500 shares of the company’s stock worth $1,338,000 after buying an additional 15,000 shares during the period. 97.48% of the stock is currently owned by institutional investors and hedge funds.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.